Download pdf
Introducing amoxicillin and azithromycin in treating streptococcal pharyngitis
- 1 Nanjing Foreign Language School
* Author to whom correspondence should be addressed.
Abstract
Streptococcal pharyngitis, also known as strep throat, is a disease caused by bacterial infection that could make one to feel scratchy and sore in one's throat. As a disease found mostly in children, strep throat could lead to various infections and complications such as fever or lung infection. In this work, the author will investigate several aspects of this disease, including 1. its symptoms, consisting of detailed description of disorders on patients, similarities and differences between some other common diseases. 2. its causes, emphasizing on the structure and characteristics of the bacteria that is causing infection. 3. its influences in a worldwide scale, including number of infected and the negative impact that it brings to the infected. The two antibiotics used to treat streptococcal pharyngitis, which are amoxicillin and azithromycin, will be emphatically discussed. The discussion will be mainly about the two drugs’ chemical structures and properties, mechanics of treatment, how they kill and eliminate pathogens, and their various effects - positive ones and side effects- on patients.
Keywords
amoxicillin, azithromycin, streptococcal pharyngitis, chemical structures, side effects
[1]. https://www.mayoclinic.org/diseases-conditions/strep-throat/symptoms-causes/syc-20350338
[2]. Ibrahim J, Eisen JA, Jospin G, Coil DA, Khazen G, Tokajian S. Genome Analysis of Streptococcus pyogenes Associated with Pharyngitis and Skin Infections. PLoS One. 2016;11(12): e0168177
[3]. https://www.lji.org/ “considering an average number of around 600 million people a year contracting such disease”
[4]. https://www.drugs.com/ “tonsillitis, bronchitis, pneumonia, and infections of the ear, nose, throat, skin, or urinary tract”
[5]. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 33613, Amoxicillin. Retrieved July 25, 2023 from https://pubchem.ncbi.nlm.nih.gov/compound/Amoxicillin.
[6]. Weber DJ, Tolkoff-Rubin NE, Rubin RH. Amoxicillin and potassium clavulanate: an antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Pharmacotherapy. 1984 May-Jun;4(3):122-36.
[7]. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 447043, Azithromycin. Retrieved July 30, 2023 from https://pubchem.ncbi.nlm.nih.gov/compound/Azithromycin.
[8]. Jelić D, Antolović R. From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials. Antibiotics (Basel). 2016 Sep 01;5(3)
[9]. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Oct 20, 2020. Amoxicillin.
[10]. Barboza JL, Okun MS, Moshiree B. The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. Expert Opin Pharmacother. 2015;16(16):2449-64.
Cite this article
Gao,C. (2024). Introducing amoxicillin and azithromycin in treating streptococcal pharyngitis. Theoretical and Natural Science,47,97-101.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Environmental Geoscience and Earth Ecology
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).